Ontology highlight
ABSTRACT: Background
Third coronavirus disease 2019 (COVID-19) vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults.Methods
We measured circulating antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and omicron (BA.1) strains from prevaccine up to 1 month following the third dose, in 151 adults aged 24-98 years who received COVID-19 mRNA vaccines.Results
Following 2 vaccine doses, humoral immunity was weaker, less functional, and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. One month after the third dose, antibody concentrations and function exceeded post-second-dose levels, and responses in older adults were comparable in magnitude to those in younger adults at this time. Humoral responses against omicron were universally weaker than against the ancestral strain after both the second and third doses. Nevertheless, after 3 doses, anti-omicron responses in older adults reached equivalence to those in younger adults. One month after 3 vaccine doses, the number of chronic health conditions, but not age, was the strongest consistent correlate of weaker humoral responses.Conclusions
Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults.
SUBMITTER: Mwimanzi F
PROVIDER: S-EPMC9129202 | biostudies-literature | 2022 Sep
REPOSITORIES: biostudies-literature
Mwimanzi Francis F Lapointe Hope R HR Cheung Peter K PK Sang Yurou Y Yaseen Fatima F Umviligihozo Gisele G Kalikawe Rebecca R Datwani Sneha S Omondi F Harrison FH Burns Laura L Young Landon L Leung Victor V Agafitei Olga O Ennis Siobhan S Dong Winnie W Basra Simran S Lim Li Yi LY Ng Kurtis K Pantophlet Ralph R Brumme Chanson J CJ Montaner Julio S G JSG Prystajecky Natalie N Lowe Christopher F CF DeMarco Mari L ML Holmes Daniel T DT Simons Janet J Niikura Masahiro M Romney Marc G MG Brumme Zabrina L ZL Brockman Mark A MA
The Journal of infectious diseases 20220901 6
<h4>Background</h4>Third coronavirus disease 2019 (COVID-19) vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults.<h4>Methods</h4>We measured circulating antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and omicron (BA.1) strains from prevaccine up to 1 month following the third dose, in 151 adults aged 24-9 ...[more]